Clinical Influence of Different Surface Treatments on Implant Stabiity

Launched by INTERNATIONAL PIEZOSURGERY ACADEMY · Feb 4, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how different treatments for the surfaces of dental implants affect their stability in patients who need implants in the upper premolar and first molar areas. Specifically, it will compare implants that are treated with vacuum-plasma activation, ozonated oil, and those that are not activated at all. The study aims to gather information on how well these implants hold in place after being placed in the mouth.

To be eligible for the study, participants should be at least 18 years old and need implants in the specified areas of their mouth. They must have healthy bone in the area where the implant will go, with no recent tooth extractions needing additional bone support. Good oral hygiene is important, and participants should not have certain medical conditions, such as uncontrolled diabetes or recent heart issues. Those who join the study can expect to have their implants monitored over time to see how well they are doing, and they will need to attend follow-up visits. It's a valuable opportunity to contribute to understanding the best ways to support dental implants and improve patient care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age older than 18 years old;
• • Indication for an implant-supported rehabilitation in the left and right upper premolar/first molar areas;
• • The area in which the implants will be placed must have had at least 6 months of healing;
• • No use of grafts or bone substitutes following tooth extraction;
• • Bone volume measuring at least 10 mm in height and 6 mm in width;
• • Absence or decision to not wear a removable prosthesis during the healing period;
• • Patients with good and stable oral hygiene;
• • Signed informed consent form.
• Exclusion Criteria:
• • Acute myocardial infarction within the previous six months;
• • Uncontrolled bleeding disorders;
• • Uncontrolled diabetes (HBA1c \> 7.5%);
• • Radiotherapy in the head-neck area in the previous 48 months;
• • Immunocompromised patients (es. AIDS / chemotherapy);
• • Current or previous treatment with antiresorptive drugs via intravenous injection;
• • Psychological or psychiatric disease;
• • Alcohol and /or drugs abuse;
• • Heavy smokers (more than 10 cigarettes / day);
• • Plaque index \>20% and/or bleeding on probing \>10%
• • Pregnant or breastfeeding patients;
• • Patients refusing to participate in follow-up checks.